Epstein-Barr Nuclear Antigen, Human, IgM, BioAssay(TM) ELISA Kit (EBNA)

The United States Biological Epstein-Barr Nuclear Antigen, Human, IgM, BioAssay(TM) ELISA Kit is intended for the detection of IgM antibody to Epstein Barr Virus Nuclear Antigen-1 in human sera and plasma.\n\nDetection of the Epstein-Barr virus was first described in 1964 by Epstein, Achong, and Barr using electron microscopic studies of cultured lymphoblasts derived from patients with Burkitt's lymphoma. EBV is classified as a member of the herpes-virus family based upon it's characteristic morphology. EBV infection may demonstrate a wide spectrum of clinical symptoms. The majority of primary EBV infections are transmitted via saliva, occur during childhood, and are subclinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years; 80% by adulthood. Transfusion- associated EBV infections have also been reported3. In young adults, EBV infection may be clinically manifested as Infectious Mononucleosis (IM) with typical symptoms of sore throat, fever, and lymphadenopathy. College students and military personnel are often cited as a high morbidity incidence population for IM.\nInfection of the target cells leads to two forms of viral cycles; 1) latent, nonproductive and 2) productive, replicative infections. In both cycles, one of the earliest antigens expressed is lymphocyte-detected membrane antigen, a cell-surface antigen recognized by T-cells. It has been well established that most individuals exposed to EBV develop a heterophile antibody response. Expression of EBNA-1 either follows or parallels membrane antigen at 12 to 24 hours post infection. EBNA-1 is found as nonstructural, intranuclear antigen(s), present in all EBV-transformed cell lines as in tumors from Burkitt's and nasopharyngeal carcinoma patients. In the fully productive, replicative cycle, the synthesis of antigen follows EBNA-1. The viral capsid antigen complex (VCA) appears late in the replicative cycle. It has recently become apparent that EBNA-1 is probably not a single antigenic moiety, but a multicomponent antigen complex, on the basis of reactivities of serum from different classes of patients. The major component EBNA-1 has been purified and sequenced in its entirety. Antibody levels of EBNA-1 IgG, are diagnostic in determining acute and convalescent stages in IM IgG antibodies to EBNA-1 are rarely present in acute IM and rise during convalescence. They will rise to a plateau level in three months to a year and will normally persist for life.\n \nKit Components:\n1. Microtiter Plate: 1x96 wells\n2. Absorbent Solution: 1X22 ml\n3. Wash Buffer,10X: 1X100ml\n4. Tetramethylbenzidine (TMB): 1x15ml\n5. Enzyme conjugate: 1X12 ml \n6. Cut-off Calibrator: 1X150ul\n7. Negative control: 1X150ul\n8. Positive control: 1X150ul\n9. Stop solution:1X12 ml (2 N Hcl)\n \nStorage and Stability:\nStore all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

T8171-92G

Size

1Kit

Applications

ELISA

Reactivities

Hum

References

1. Epstein, M.A., B.B. Achong, and Y.M. Barr. 1964. Virus particles in Cultured Lymphoblasts from Burkitt's Lymphoma. In: Lancet 1:702-703. 2. Epstein, M.A., et al., Sympos. Monogr. 4:69-82. 3. Schooley, R.T. and R. Dolin. 1985. Epstein-Barr Virus Infectious Mononucleosis). In: Principles and Practice of Infectious Diseases, 2nd Edition. Mandell, G.L., R.G. Douglas, and J.E. Bennett. (eds). John Wiley and Sons, New York. pp 97-982. 4. Lennette, E.T. 1988. Herpesviridae: Epstein-Barr Virus. In: Laboratory Diagnosis of Infectious Diseases, Principles and Practice. Vol. Ll. Lennette, E.H., Halonen, P., Murphy, F.A., eds. Springer- Verlag, NY. Pp. 230- 246. 5. Lennette, E.T. and W. Henle. 1987. Epstein-Barr Virus Infections: Clinical and Serological Features. Laboratory Management June: pp. 22-28. 6. Henle G., et al., Journal of infectious Diseases. 130:231-239.